Home
Conditions
Refractory Multiple Myeloma

Clinical trial condition

Refractory Multiple Myeloma

Explore clinical trials studying Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

153 public trials 23 recruiting studies

Refine in advanced search Browse all conditions

Refractory Multiple Myeloma trial results

Active, Not Recruiting

MMRC Horizon One: RRMM (MMRC-099)

NCT06171685

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: City of Hope Duarte, California, United States

Emory Winship Cancer Center Atlanta, Georgia, United States

University of Chicago Cancer Center Chicago, Illinois, United States

Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

View all 13 locations

View Trial Details

Active, Not Recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

NCT06400251

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

NCT06308822

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

NCT06400238

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT06357988

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +20 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

NCT06360575

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

NCT04439149

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

NCT04439188

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Weill Cornell Medicine - Multiple Myeloma Center New York, United States

View Trial Details

Refractory Multiple Myeloma

Refractory Multiple Myeloma trial results

Related conditions